Physicians’ Preferences for Bone Metastases Drug Therapy in the United States

Arellano, Jorge; Hauber, A. Brett; Mohamed, Ateesha F.; Gonzalez, Juan Marcos; Collins, Helen; Hechmati, Guy; Gatta, Francesca; Qian, Yi

doi:10.1016/j.jval.2014.10.004

Cited by 23 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…efficient mode of bta administration is a desirable aspect of this attribute. Overall, the findings in the study appear to be consistent with results from similar preference-elicitation studies among physicians in the United States 33 and Europe 34,35 , for whom both efficacy and a reduced risk of renal impairment represented the primary goals in their decision-making process.…”

Section: Discussionsupporting

confidence: 83%

Physician Preferences for Bone Metastasis Drug Therapy in Canada

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

Physician Preferences for Bone Metastasis Drug Therapy in Canada

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This consistently greater compliance observed throughout the 3-year study period confirms and extends the 1-year findings reported by Hernandez et al As suggested previously, the better compliance among denosumab patients may reflect more convenient dosing and physicians’ motivation to sustain “on-time” dosing schedules in order to achieve the full therapeutic benefit demonstrated in the denosumab clinical trials. Recent research into physician preferences for bone metastasis drug therapy indicates that the most important considerations are delaying SREs and worsening of pain, while minimizing the risk of renal impairment [16, 23]. Renal toxicity is also an important factor when patients consider BTA therapy, and the known renal toxicity of IV BPs complicates treatment since renal function must be closely monitored in patients using zoledronic acid and doses may be delayed or skipped depending on the patient serum creatinine levels [16, 24, 25].…”

Section: Discussionmentioning

confidence: 99%

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States

Qian

Bhowmik

Kachru

et al. 2017

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

PurposeThis study examined real-world long-term use of guideline-recommended bone targeted agents (BTA) among patients with metastatic solid tumors.MethodsAdults with a solid tumor diagnosis followed by a bone metastasis diagnosis in 2012–2014 were identified from electronic medical records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients initiated zoledronic acid (ZA) or denosumab on or after the bone metastasis diagnosis and were followed through last clinic visit by 30 June 2015. We describe time to BTA initiation, compliance (≥12 administrations in a year), switching, and non-persistence (switch or ≥90 day gap in therapy), by agent and follow-up period.ResultsThe majority of the 14,881 study patients (50% female, 65% age ≥65 years) had breast (33%), prostate (26%), or lung (26%) tumors. Half of all patients initiated on each agent, with denosumab initiations exceeding ZA initiations in 2014. Most (91% denosumab, 93% ZA) initiations occurred within 3 months of bone metastasis diagnosis. At 1, 2, and 3 years post-initiation, denosumab patients were less likely to switch agents (4, 3, and 1% versus 14, 12, and 11%) and more likely to be compliant (50, 37, and 31% versus 41, 26, and 6%). Median time to non-persistence was 25.9 months for denosumab and 17.2 months for ZA, p < 0.0001.ConclusionsThis is the first study reporting long-term treatment patterns for the two primary BTAs used in the USA. The greater compliance and longer persistence observed among denosumab patients may improve treatment effectiveness achieved in the real-world setting.Electronic supplementary materialThe online version of this article (doi:10.1007/s00520-017-3583-1) contains supplementary material, which is available to authorized users.

show abstract

“…Although early applications were used to quantify process utility [9,10], more recent applications have focused on patient preferences for health status [11,12], screening [13], prevention [14,15], pharmaceutical treatment [16,17], therapeutic devices [18,19], diagnostic testing [20,21], and end-of-life care [22,23]. In addition, conjoint analysis methods have been used to study decision making among stakeholders other than patients, including clinicians [24][25][26], caregivers [25,27], and the general public [28,29].…”

Section: Introductionmentioning

confidence: 99%

Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force

et al. 2016

Self Cite

View full text Add to dashboard Cite

Conjoint analysis is a stated-preference survey method that can be used to elicit responses that reveal preferences, priorities, and the relative importance of individual features associated with health care interventions or services. Conjoint analysis methods, particularly discrete choice experiments (DCEs), have been increasingly used to quantify preferences of patients, caregivers, physicians, and other stakeholders. Recent consensus-based guidance on good research practices, including two recent task force reports from the International Society for Pharmacoeconomics and Outcomes Research, has aided in improving the quality of conjoint analyses and DCEs in outcomes research. Nevertheless, uncertainty regarding good research practices for the statistical analysis of data from DCEs persists. There are multiple methods for analyzing DCE data. Understanding the characteristics and appropriate use of different analysis methods is critical to conducting a well-designed DCE study. This report will assist researchers in evaluating and selecting among alternative approaches to conducting statistical analysis of DCE data. We first present a simplistic DCE example and a simple method for using the resulting data. We then present a pedagogical example of a DCE and one of the most common approaches to analyzing data from such a question format-conditional logit. We then describe some common alternative methods for analyzing these data and the strengths and weaknesses of each alternative. We present the ESTIMATE checklist, which includes a list of questions to consider when justifying the choice of analysis method, describing the analysis, and interpreting the results.

show abstract

Physicians’ Preferences for Bone Metastases Drug Therapy in the United States

Cited by 23 publications

References 25 publications

Physician Preferences for Bone Metastasis Drug Therapy in Canada

Physician Preferences for Bone Metastasis Drug Therapy in Canada

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States

Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force

Contact Info

Product

Resources

About